Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Core Laboratories Inc (NYSE: CLB) closed the day trading at $10.33 down -5.92% from the previous closing price of $10.98. In other words, the price has decreased by -$5.92 from its previous closing price. On the day, 1.08 million shares were traded. CLB stock price reached its highest trading level at $10.945 during the session, while it also had its lowest trading level at $10.31.
Ratios:
For a better understanding of CLB, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.53 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.35. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 2.27. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.64.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Citigroup on March 12, 2025, Upgraded its rating to Neutral and sets its target price to $16 from $15 previously.
On June 30, 2023, Citigroup Downgraded its rating to Sell which previously was Neutral and also lowered its target price recommendation from $22 to $21.
BofA Securities Downgraded its Neutral to Underperform on April 18, 2023, while the target price for the stock was maintained at $21.50.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLB now has a Market Capitalization of 484413376 and an Enterprise Value of 637786368. As of this moment, Core’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.61, and their Forward P/E ratio for the next fiscal year is 12.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.34. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.94 while its Price-to-Book (P/B) ratio in mrq is 1.84. Its current Enterprise Value per Revenue stands at 1.233 whereas that against EBITDA is 10.17.
Stock Price History:
The Beta on a monthly basis for CLB is 1.39, which has changed by -0.45631582 over the last 52 weeks, in comparison to a change of 0.118204355 over the same period for the S&P500. Over the past 52 weeks, CLB has reached a high of $21.83, while it has fallen to a 52-week low of $9.72. The 50-Day Moving Average of the stock is -10.74%, while the 200-Day Moving Average is calculated to be -23.10%.
Shares Statistics:
Over the past 3-months, CLB traded about 497.98K shares per day on average, while over the past 10 days, CLB traded about 480420 shares per day. A total of 46.54M shares are outstanding, with a floating share count of 46.39M. Insiders hold about 1.08% of the company’s shares, while institutions hold 111.70% stake in the company. Shares short for CLB as of 1759190400 were 6883429 with a Short Ratio of 13.82, compared to 1756425600 on 8315209. Therefore, it implies a Short% of Shares Outstanding of 6883429 and a Short% of Float of 39.189997.
Dividends & Splits
CLB’s forward annual dividend rate is 0.04, up from 0.04 a year ago. Against a Trailing Annual Dividend Yield of 0.0036429872. The stock’s 5-year Average Dividend Yield is 0.26. The current Payout Ratio is 5.97% for CLB, which recently paid a dividend on 2025-08-04 with an ex-dividend date of 2025-08-04. Stock splits for the company last occurred on 2010-07-09 when the company split stock in a 2:1 ratio.
Earnings Estimates
At present, 2.0 analysts are actively evaluating the performance of Core Laboratories Inc (CLB) in the stock market.The consensus estimate for the next quarter is $0.18, with high estimates of $0.19 and low estimates of $0.17.
Analysts are recommending an EPS of between $0.73 and $0.72 for the fiscal current year, implying an average EPS of $0.73. EPS for the following year is $0.85, with 2.0 analysts recommending between $0.92 and $0.78.
Revenue Estimates
3 analysts predict $131.73M in revenue for. The current quarter. It ranges from a high estimate of $134.01M to a low estimate of $129.58M. As of. The current estimate, Core Laboratories Inc’s year-ago sales were $134.4MFor the next quarter, 3 analysts are estimating revenue of $129.13M. There is a high estimate of $130.45M for the next quarter, whereas the lowest estimate is $126.83M.
A total of 3 analysts have provided revenue estimates for CLB’s current fiscal year. The highest revenue estimate was $518.85M, while the lowest revenue estimate was $510.15M, resulting in an average revenue estimate of $514.8M. In the same quarter a year ago, actual revenue was $523.85MBased on 3 analysts’ estimates, the company’s revenue will be $526.55M in the next fiscal year. The high estimate is $551.5M and the low estimate is $508.13M.
